{
    "title": "Gloomy COVID drug data shows why big, randomized trials matter",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8848233/Gloomy-COVID-drug-data-shows-big-randomized-trials-matter.html",
    "date": "2020-10-16",
    "keywords": [
        "trial",
        "remdesivir",
        "solidarity",
        "drug",
        "treatment",
        "covid19",
        "week",
        "evidence",
        "university",
        "size",
        "world",
        "companys",
        "survival",
        "cut",
        "recovery",
        "time",
        "placebo",
        "data",
        "professor",
        "medicine",
        "kate",
        "kelland",
        "health",
        "verdict",
        "edge",
        "ebola",
        "benefit",
        "factor",
        "difference",
        "study",
        "response",
        "drugmaker",
        "accuracy",
        "debate",
        "panacea",
        "peter",
        "galle",
        "mainz",
        "hospital",
        "germany",
        "face",
        "value",
        "journal",
        "multicountry",
        "weight",
        "outcome",
        "mortality",
        "landray",
        "amp",
        "epidemiology",
        "oxford",
        "impact",
        "overall",
        "answer",
        "andrew",
        "expert",
        "pharmacology",
        "term",
        "death",
        "hydroxychloroquine",
        "combination",
        "lopinavirritonavir",
        "interferon",
        "richard",
        "peto",
        "statistician",
        "design",
        "quality",
        "randomisation",
        "followup",
        "reporting",
        "burger",
        "frankfurt",
        "stephanie",
        "nebehay",
        "geneva",
        "francesco",
        "guarascio",
        "carmel",
        "mark",
        "potter"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}